Moderna (MRNA) Reports Positive Interim Phase 1 Data for mRNA Flu Vaccine and Provides Program Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles down after choppy session as investors weigh Hormuz talks
- Meta to pay up to $16.68 billion in mass social media settlement
- Anthropic agrees to $45bn cloud computing deal with Nscale - report
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
Moderna's (MRNA) COVID-19 Vaccine Manufactured in Korea by Samsung Granted Marketing Authorization from Ministry of Food and Drug Safety of Korea
December 14, 2021 5:46 AM ESTModerna (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced today that the Ministry of Food and Drug Safety of Korea (MFDS) has issued a marketing authorization for Spikevax®, Moderna's COVID-19 vaccine (mRNA-1273) manufactured by Samsung Biologics, a leading global CDMO providing fully integrated end-to-end contract development and manufacturing services.
This marketing authorization obtained by Moderna Korea officially allows the Moderna's COVID-19 vaccine manufactured at Samsung Biologics' local pharmaceutical production facilities to be distributed within Korea and... More
Moderna (MRNA) Declines 7% Pre-Open Following Interim Phase 1 Data for mRNA Flu Vaccine and Program Update
December 10, 2021 7:13 AM ESTModerna (NASDAQ: MRNA) Declines 7% Pre-Open Following Interim Phase 1 Data for mRNA Flu Vaccine and Program Update
... MoreStocks with Implied Volatility Movement
December 10, 2021 5:06 AM ESTModerna (NASDAQ: MRNA) volatility index movement decreasing vs. 30D HV
... MoreModerna (MRNA) Will Host Conference Call on Phase 1 Interim Analysis for mRNA Flu Vaccine on Friday, December 10
December 9, 2021 4:44 PM ESTModerna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it will host a live conference call and webcast on the Phase 1 interim analysis of its seasonal influenza vaccine candidate, mRNA-1010 tomorrow, Friday, December 10, 2021 at 8:00... More
CDC Expands Booster Recommendations To 16-and-17-year-olds - Bloomberg
December 9, 2021 2:30 PM ESTCDC Expands Booster Recommendations To 16-and-17-year-olds - Bloomberg
... MoreBioNTech (BNTX) and Pfizer (PFE) Beneficiaries From Lower Omicron Vaccine Efficacy - SVB Leerink
December 9, 2021 6:28 AM ESTSVB Leerink analyst Daina Graybosch reiterated Market Perform ratings on BioNTech (NASDAQ: BNTX) and Pfizer (NYSE: PFE) after the companies confirmed that the protection conferred by vaccination with Comirnaty is 20-fold lower against Omicron compared to wild type... More
Moderna (MRNA) on Watch as Pfizer/BioNTech SE Three Dose Regimen Neutralizes Omicron
December 8, 2021 7:04 AM ESTModerna (NASDAQ: MRNA) shares are on watch as rivals Pfizer/BioNTech SE said three of their vaccine doses neutralize the Omicron variant. Both use similar mRNA technology, so it could be assumed that Moderna's jab has the same impact. Shares of MRNA are down 2% in pre-open trading.
... More